NCT06112301 - Pivotal, Clinical Study for the Accuracy Evaluation of the IdentiClone Dx IGH Assay | Biotech Hunter

Enrollment

250

Participants

Timeline

Start Date

January 2, 2024

Primary Completion Date

November 6, 2024

Study Completion Date

November 6, 2024

Conditions

B-Cell Lymphoproliferative Disorder

Interventions

DIAGNOSTIC_TEST

IdentiClone Dx IGH (IC IGH Dx) Assay

The IdentiClone Dx IGH Assay is an in vitro diagnostic product intended for qualitative, capillary electrophoresis based-detection of clonality in immunoglobulin heavy chain gene rearrangements (IGH) in peripheral blood specimens as an adjunctive method for the diagnosis of B-cell lymphoproliferative disease

Trial Locations (3)

85399

LabPMM GmbH, Hallbergmoos

92103

Invivoscribe, Inc., San Diego

210-0821

LabPMM GK, Kawasaki-shi

All Listed Sponsors

lead

Invivoscribe, Inc.

INDUSTRY